{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:01:10Z","timestamp":1792195270796,"version":"4.4.0"},"reference-count":39,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.3201\/eid3204.251906","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:26:50Z","timestamp":1774981610000},"source":"Crossref","is-referenced-by-count":3,"title":["Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance"],"prefix":"10.3201","volume":"32","author":[{"given":"Elif","family":"Karaaslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Whitesell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Malenfant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasongo Kayembe","family":"Jolie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enogo","family":"Koivogui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba Michel","family":"Grovogui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boubacar","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouonan","family":"Gbamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Corvil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaba","family":"Boumbaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimou","family":"Camara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina F.","family":"Spiropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3204.251906-202603301632-R1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease.","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"key-10.3201\/eid3204.251906-202603301632-R2","unstructured":"World Health Organization. Ebola virus disease [cited 2025 Mar 21]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ebola-virus-disease"},{"key":"key-10.3201\/eid3204.251906-202603301632-R3","doi-asserted-by":"publisher","first-page":"S465","DOI":"10.1093\/infdis\/jiad352","article-title":"The multiple origins of Ebola disease outbreaks.","volume":"228","author":"Judson","year":"2023","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid3204.251906-202603301632-R4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jiph.2023.10.020","article-title":"Case fatality rate for Ebola disease, 1976-2022: A meta-analysis of global data.","volume":"17","author":"Izudi","year":"2024","journal-title":"J Infect Public Health"},{"key":"key-10.3201\/eid3204.251906-202603301632-R5","doi-asserted-by":"publisher","first-page":"e001955","DOI":"10.1136\/bmjgh-2019-001955","article-title":"Forty-two years of responding to Ebola virus outbreaks in Sub-Saharan Africa: a review.","volume":"5","author":"Rugarabamu","year":"2020","journal-title":"BMJ Glob Health"},{"key":"key-10.3201\/eid3204.251906-202603301632-R6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.","volume":"18","author":"Huttner","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3204.251906-202603301632-R7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!).","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"key-10.3201\/eid3204.251906-202603301632-R8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S1473-3099(23)00819-8","article-title":"Case fatality risk among individuals vaccinated with rVSV\u0394G-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo.","volume":"24","author":"Coulborn","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3204.251906-202603301632-R9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3201\/eid2201.151410","article-title":"Effectiveness of ring vaccination as control strategy for Ebola virus disease.","volume":"22","author":"Kucharski","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid3204.251906-202603301632-R10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3204.251906-202603301632-R11","doi-asserted-by":"publisher","first-page":"27944","DOI":"10.1038\/srep27944","article-title":"Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine.","volume":"6","author":"Farooq","year":"2016","journal-title":"Sci Rep"},{"key":"key-10.3201\/eid3204.251906-202603301632-R12","doi-asserted-by":"publisher","first-page":"7666","DOI":"10.1038\/s41467-024-51453-z","article-title":"Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.","volume":"15","author":"Wiedemann","year":"2024","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid3204.251906-202603301632-R13","unstructured":"World Health Organization. Ebola, West Africa, 2014\u20132016 [cited 2024 Nov 6]. https:\/\/www.who.int\/emergencies\/situations\/ebola-outbreak-2014-2016-West-Africa"},{"key":"key-10.3201\/eid3204.251906-202603301632-R14","doi-asserted-by":"crossref","unstructured":"Liu J, Trefry JC, Babka AM, Schellhase CW, Coffin KM, Williams JA,  Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors. Sci Transl Med. 2022;14:eabi5229. 10.1126\/scitranslmed.abi5229","DOI":"10.1126\/scitranslmed.abi5229"},{"key":"key-10.3201\/eid3204.251906-202603301632-R15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijid.2015.12.011","article-title":"Recurrence and reinfection\u2014a new paradigm for the management of Ebola virus disease.","volume":"43","author":"MacIntyre","year":"2016","journal-title":"Int J Infect Dis"},{"key":"key-10.3201\/eid3204.251906-202603301632-R16","unstructured":"Valayer S, Alexandre M, Prague M, Beavogui AH, Doumbia S, Kieh M,  Evaluation of waning of IgG antibody responses after rVSV\u0394G-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial. Emerg Microbes Infect. 2025;14(1):0.\n                      PMID: 39559990"},{"key":"key-10.3201\/eid3204.251906-202603301632-R17","doi-asserted-by":"publisher","first-page":"101110","DOI":"10.1016\/j.lanmic.2025.101110","article-title":"Uganda launches vaccine trial for Sudan virus disease.","volume":"6","author":"Adepoju","year":"2025","journal-title":"Lancet Microbe"},{"key":"key-10.3201\/eid3204.251906-202603301632-R18","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa2501073","article-title":"rVSV\u0394G-LASV-GPC Study Group. Safety and immunogenicity of an rVSV Lassa Fever vaccine candidate.","volume":"393","author":"Malkin","year":"2025","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3204.251906-202603301632-R19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41541-025-01343-2","article-title":"A single-cycle recombinant VSV vaccine displaying the Hendra virus glycoprotein uniformly protects against Hendra and Nipah virus challenge.","volume":"11","author":"Pigeaud","year":"2026","journal-title":"NPJ Vaccines"},{"key":"key-10.3201\/eid3204.251906-202603301632-R20","doi-asserted-by":"publisher","first-page":"2265660","DOI":"10.1080\/22221751.2023.2265660","article-title":"Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-\u0394G-ZEBOV-GP vaccination.","volume":"12","author":"Kainulainen","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"key-10.3201\/eid3204.251906-202603301632-R21","doi-asserted-by":"publisher","first-page":"12330","DOI":"10.1038\/s41598-021-91300-5","article-title":"High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay.","volume":"11","author":"Kainulainen","year":"2021","journal-title":"Sci Rep"},{"key":"key-10.3201\/eid3204.251906-202603301632-R22","doi-asserted-by":"publisher","first-page":"e1002248","DOI":"10.1371\/journal.ppat.1002248","article-title":"Structure of the vesicular stomatitis virus N0-P complex.","volume":"7","author":"Leyrat","year":"2011","journal-title":"PLoS Pathog"},{"key":"key-10.3201\/eid3204.251906-202603301632-R23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/pro.587","article-title":"The N(0)-binding region of the vesicular stomatitis virus phosphoprotein is globally disordered but contains transient \u03b1-helices.","volume":"20","author":"Leyrat","year":"2011","journal-title":"Protein Sci"},{"key":"key-10.3201\/eid3204.251906-202603301632-R24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41541-024-00931-y","article-title":"Crimean Congo hemorrhagic fever virus nucleoprotein and GP38 subunit vaccine combination prevents morbidity in mice.","volume":"9","author":"Karaaslan","year":"2024","journal-title":"NPJ Vaccines"},{"key":"key-10.3201\/eid3204.251906-202603301632-R25","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"key-10.3201\/eid3204.251906-202603301632-R26","doi-asserted-by":"publisher","first-page":"7298","DOI":"10.1038\/s41467-022-34923-0","article-title":"Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus.","volume":"13","author":"Durie","year":"2022","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid3204.251906-202603301632-R27","doi-asserted-by":"publisher","first-page":"e0215457","DOI":"10.1371\/journal.pone.0215457","article-title":"Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples.","volume":"14","author":"Rudge","year":"2019","journal-title":"PLoS One"},{"key":"key-10.3201\/eid3204.251906-202603301632-R28","doi-asserted-by":"publisher","first-page":"16128","DOI":"10.1038\/nmicrobiol.2016.128","article-title":"Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.","volume":"1","author":"Pallesen","year":"2016","journal-title":"Nat Microbiol"},{"key":"key-10.3201\/eid3204.251906-202603301632-R29","doi-asserted-by":"publisher","first-page":"e929","DOI":"10.1093\/infdis\/jiae155","article-title":"Ebola virus\u2013specific neutralizing antibody persists at high levels in survivors 2 years after resolution of disease in a Sierra Leonean cohort.","volume":"230","author":"Bond","year":"2024","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid3204.251906-202603301632-R30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/infdis\/jiz364","article-title":"Survivors of Ebola virus disease develop polyfunctional antibody responses.","volume":"221","author":"Gunn","year":"2020","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid3204.251906-202603301632-R31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1128\/JCM.01979-16","article-title":"Development of a sensitive and specific serological assay based on Luminex technology for detection of antibodies to zaire Ebola virus.","volume":"55","author":"Ayouba","year":"2016","journal-title":"J Clin Microbiol"},{"key":"key-10.3201\/eid3204.251906-202603301632-R32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jviromet.2018.02.018","article-title":"Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay.","volume":"255","author":"Logue","year":"2018","journal-title":"J Virol Methods"},{"key":"key-10.3201\/eid3204.251906-202603301632-R33","doi-asserted-by":"publisher","first-page":"6599","DOI":"10.1016\/j.vaccine.2022.09.037","article-title":"Immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine (ERVEBO\u00ae) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2\/3 trials.","volume":"40","author":"Simon","year":"2022","journal-title":"Vaccine"},{"key":"key-10.3201\/eid3204.251906-202603301632-R34","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"PREVAIL I Study Group. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia.","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3204.251906-202603301632-R35","doi-asserted-by":"publisher","first-page":"104186","DOI":"10.1016\/j.ebiom.2022.104186","article-title":"Ebola-Detect: A differential serodiagnostic assay for Ebola virus infections and surveillance in the presence of vaccine-induced antibodies.","volume":"82","author":"Ravichandran","year":"2022","journal-title":"EBioMedicine"},{"key":"key-10.3201\/eid3204.251906-202603301632-R36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/infdis\/jiy565","article-title":"Detectable vesicular stomatitis virus (VSV)\u2013specific humoral and cellular immune responses following VSV\u2013Ebola virus vaccination in humans.","volume":"219","author":"Poetsch","year":"2019","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid3204.251906-202603301632-R37","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.vaccine.2023.01.059","article-title":"Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSV\u0394G-ZEBOV-GP).","volume":"41","author":"Raabe","year":"2023","journal-title":"Vaccine"},{"key":"key-10.3201\/eid3204.251906-202603301632-R38","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/infdis\/jiae632","article-title":"Vector induced humoral responses after rVSV\u0394G-ZEBOV-GP immunization identify vaccinated individuals and correlate with Ebola virus glycoprotein antibodies.","volume":"232","author":"Chandrasekaran","year":"2025","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid3204.251906-202603301632-R39","doi-asserted-by":"publisher","first-page":"e0286479","DOI":"10.1371\/journal.pone.0286479","article-title":"Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo.","volume":"18","author":"Zola Matuvanga","year":"2023","journal-title":"PLoS One"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:26:50Z","timestamp":1774981610000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/32\/4\/25-1906_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3204.251906","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}